Showing results (191-200 of 396) with videos related to
Sort By:
Pageof 40
The Journal of Urology|October 10, 2019
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant TrialZiho Lee, Opeyemi A Jegede, Naomi B Haas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, et al.Cancer|October 5, 2017
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumorsPhilippe L Bédard, Michael A Davies, Scott Kopetz, et al.Journal of the National Cancer Institute|February 7, 2016
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant MelanomaFrancesco Sabbatino, Yangyang Wang, Giosuè Scognamiglio, et al.Science Signaling|September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growthJuxiang Cao, Xiangpeng Dai, Lixin Wan, et al.European Journal of Cancer (Oxford, England : 1990)|January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanomaPaolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.The Oncologist|February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic ControlChristopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.Cancer Research|October 3, 2007
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiationJohn P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibodyRobert H Vonderheide, Keith T Flaherty, Magi Khalil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersErica L Carpenter, Rosemarie Mick, Andrew J Rech, et al.Pageof 40